Effectiveness and safety of ustekinumab in bio-naive Crohn's disease patients: a multicentre observational retrospective study.

ABSTRACT:

Background

Clinical trials have demonstrated the efficacy and safety of ustekinumab in Crohn's disease (CD). However, more data are necessary on the effectiveness of ustekinumab in bio-naïve patients in real-life studies.

Objectives

The aim of our study was to evaluate the effectiveness and safety of ustekinumab in patients with CD refractory or intolerant to conventional therapy and without previous exposure to biological drugs.

Design

We performed a nationwide, observational, retrospective, multicentre study including patients with CD, in which ustekinumab was used as the first biological drug.

Methods

The corticosteroid-free clinical and biological response and remission were analysed at weeks 16, 24, 52 and 72. Clinical remission was defined as Harvey-Brads

SUBMITTER: Teresa VD 

PROVIDER: S-EPMC9912551 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature